FXR has emerged in recent years as a master regulator of lipid and glucose homeostasis in the liver and of inflammatory processes at hepatic and extrahepatic sites, and a number of synthetic FXR agonists are being tested for the treatment of different hepatic and metabolic disorders[11,12] given the ability of FXR to antagonize inflammatory and fibrogenic processes. The gene discussed is NR1H4; the disease is Other metabolic disease.